Aiforia partners with Siemens Healthineers

Translation: Original published in Finnish on 9/10/2025 at 7:05 pm EEST.

Aiforia announced in a press release published on Tuesday that it has entered into a strategic partnership with Siemens Healthineers. Through the collaboration, Siemens Healthineers will begin offering Aiforia's AI-powered solutions as part of its digital pathology portfolio to its customers in Europe. We believe the agreement will support Aiforia's sales, enabling it to reach a wider customer base more efficiently and quickly. Our forecasts already include an expectation of continuous customer wins, and in our view, the press release does not directly affect the customer sample scanner capacity, which is a bottleneck for the company's growth. Therefore, it does not create immediate pressure to change our estimates. 

Partnership opens doors to sector giant's distribution network

One of Aiforia's growth strategy cornerstones is leveraging partnerships to accelerate sales and marketing. Aiforia has previously entered into partnerships that focus more on technical integration (e.g., Dedalus, Techcyte), but the Siemens collaboration is more clearly sales-oriented. In our view, the newly announced partnership is also Aiforia's most prominent to date. Siemens Healthineers is a healthcare technology giant with a strong brand, a broad customer base, and established sales channels in Europe. In light of public information, Siemens Healthineers has primarily focused on other areas of healthcare than digital pathology (e.g., medical imaging, cancer treatments, diagnostics more broadly), and the company was not on our map as a key player in the digital pathology value chain. This is, of course, natural given the earlier stage of digitalization in pathology compared to other areas of healthcare, but we interpret digital pathology as one of the company's growth areas.

For example, Siemens Healthineers offers image management systems (IMS) which, as we understand it, integrate with medical imaging, such as radiology, in addition to pathology. The partnership focuses on joint sales and marketing efforts, meaning that Siemens' local sales organizations can actively offer solutions integrated into Aiforia's platform to their own customers. This allows Aiforia to reach a broader customer base without significantly increasing its own sales resources. At best, the expansion of the existing IMS solution to digital pathology for Siemens Healthineers' broad customer portfolio of other imaging solutions could happen very efficiently, providing Aiforia with a valuable sales channel. 

However, we estimate that the acquisition of sample scanner capacity remains a key bottleneck for the use of Aiforia's software and revenue growth, and the partnership does not offer a direct solution to this. We see the partnership's role as more supportive of Aiforia's customer acquisition than as an accelerator of short-term revenue growth. The partnership naturally takes Aiforia's growth strategy another step forward, but we do not see it causing immediate pressure for changes in our forecasts, which anticipate accelerating revenue growth.